Jan Hinrich Bräsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jan Hinrich Bräsen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Heiko Schenk
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
1 shared publication Hermann Haller
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
1 shared publication- Janina Müller-Deile
Department of Nephrology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
1 shared publication - Mario Schiffer
Department of Nephrology and Hypertension, Uniklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
1 shared publication Roland Schmitt
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
1 shared publication
Latest Publications
- 29 March 2017
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 32 (6) , 444-452
Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb
Treatment of primary focal segmental glomerulosclerosis (FSGS) and its recurrence after kidney transplantation associated with rapid deterioration of kidney function remains to be challenging despite advances in immunosuppressive therapy. The presence of circulating factors has been postulated to be a pivotal player in the pathogenesis of FSGS, although suPAR and CLCF‐1 have been identified as the most promising causative factors. The potential therapeutic effect of suPAR elimination in an FSGS patient using CytoSorb, a hemoadsorption device that gained attention in the cytokine elimination in septic patients, was studied. Efficiency of total plasma exchange to remove suPAR was determined. CytoSorb hemoadsorption caused a 27.33% reduction of the suPAR level in a single treatment, whereas total plasma exchange showed a suPAR level reduction of 25.12% (n = 3; 95% confidence interval, 0.2777‐0.8090; P < 0.01), which may indicate therapeutic potential in the treatment of primary FSGS and its recurrence in a kidney transplant.
- 29 March 2017
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 32 (6) , 444-452
Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb
Treatment of primary focal segmental glomerulosclerosis (FSGS) and its recurrence after kidney transplantation associated with rapid deterioration of kidney function remains to be challenging despite advances in immunosuppressive therapy. The presence of circulating factors has been postulated to be a pivotal player in the pathogenesis of FSGS, although suPAR and CLCF‐1 have been identified as the most promising causative factors. The potential therapeutic effect of suPAR elimination in an FSGS patient using CytoSorb, a hemoadsorption device that gained attention in the cytokine elimination in septic patients, was studied. Efficiency of total plasma exchange to remove suPAR was determined. CytoSorb hemoadsorption caused a 27.33% reduction of the suPAR level in a single treatment, whereas total plasma exchange showed a suPAR level reduction of 25.12% (n = 3; 95% confidence interval, 0.2777‐0.8090; P < 0.01), which may indicate therapeutic potential in the treatment of primary FSGS and its recurrence in a kidney transplant.